Back to Search Start Over

Role of IKKε in the Metabolic Diseases: Physiology, Pathophysiology, and Pharmacology.

Authors :
Xiao QA
He Q
Li L
Song Y
Chen YR
Zeng J
Xia X
Source :
Frontiers in pharmacology [Front Pharmacol] 2022 May 19; Vol. 13, pp. 888588. Date of Electronic Publication: 2022 May 19 (Print Publication: 2022).
Publication Year :
2022

Abstract

IKKε (inhibitor of nuclear factor kappa-B kinase ε) is a member of the noncanonical NF-κB pathway. It participates in the inflammatory response and innate immunity against bacteria. In recent decades, IKKε has been closely associated with metabolic regulation. Inhibition of the IKKε pathway can improve fat deposition in the liver, reduce subcutaneous fat inflammation, and improve liver gluconeogenesis in obesity. IKKε is expected to be a new therapeutic target for metabolic diseases such as nonalcoholic fatty liver disease, diabetes, and obesity. Herein, we summarize the structural characterization, physiological function, and pathological role of IKKε in metabolic diseases and small molecule inhibitors of IKKε.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Xiao, He, Li, Song, Chen, Zeng and Xia.)

Details

Language :
English
ISSN :
1663-9812
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Academic Journal
Accession number :
35662709
Full Text :
https://doi.org/10.3389/fphar.2022.888588